| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 37,672 | 38,725 | ||
| Investments | 8,205 | 12,972 | ||
| Accounts receivable, net | 31,877 | 32,932 | ||
| Inventory | 3,966 | 4,992 | ||
| Prepaid expenses and other current assets | 8,026 | 8,249 | ||
| Total current assets | 89,746 | 97,870 | ||
| Property and equipment, net | 122 | 244 | ||
| Operating lease right-of-use assets | 4,680 | 5,081 | ||
| Restricted cash | 350 | 350 | ||
| Other assets | 1,334 | 1,334 | ||
| Total assets | 96,232 | 104,879 | ||
| Accounts payable | 5,392 | 2,597 | ||
| Accrued expenses | 66,328 | 62,929 | ||
| Convertible senior notes due 2025 | 250 | 24,484 | ||
| Senior secured term loan | 12,500 | 6,250 | ||
| Operating lease liabilities | 922 | 1,383 | ||
| Other current liabilities | 1,765 | 1,573 | ||
| Total current liabilities | 87,157 | 99,216 | ||
| Convertible senior notes due 2029 | 68,602 | 62,684 | ||
| Convertible senior notes due 2025, net of current portion | 24,246 | - | ||
| Senior secured term loan, net of current portion | 83,895 | 89,566 | ||
| Deferred royalty obligation | 73,499 | 73,499 | ||
| Common stock warrants | 7,965 | 4,333 | ||
| Operating lease liabilities, net of current portion | 6,008 | 6,251 | ||
| Other liabilities | 14,118 | 8,256 | ||
| Total liabilities | 365,490 | 343,805 | ||
| Common stock, 0.0001 par value 53,333 shares authorized 8,702 and 8,413 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 13 | 13 | ||
| Additional paid-in capital | 1,388,289 | 1,385,486 | ||
| Accumulated other comprehensive loss | -259 | -251 | ||
| Accumulated deficit | -1,657,301 | -1,624,174 | ||
| Total stockholders' deficit | -269,258 | -238,926 | ||
| Total liabilities and stockholders' deficit | 96,232 | 104,879 | ||
Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. (KPTI)